The estimated Net Worth of A J Kazimi is at least $9.37 million dollars as of 1 December 2021. Mr. Kazimi owns over 394 units of Cumberland Pharmaceuticals stock worth over $7,790,837 and over the last 15 years he sold CPIX stock worth over $100,003. In addition, he makes $1,477,300 as Chairman of the Board et Chief Executive Officer at Cumberland Pharmaceuticals.
A has made over 16 trades of the Cumberland Pharmaceuticals stock since 2009, according to the Form 4 filled with the SEC. Most recently he bought 394 units of CPIX stock worth $1,789 on 1 December 2021.
The largest trade he's ever made was exercising 53,000 units of Cumberland Pharmaceuticals stock on 31 December 2009 worth over $349,800. On average, A trades about 1,897 units every 93 days since 2009. As of 1 December 2021 he still owns at least 5,770,563 units of Cumberland Pharmaceuticals stock.
You can see the complete history of Mr. Kazimi stock trades at the bottom of the page.
A. J. Kazimi serves as Chairman of the Board, Chief Executive Officer of the Company. His career includes 30 years in the biopharmaceutical industry. At Cumberland, he has overseen the development and FDA approval of the company’s Acetadote® and Caldolor® brands, while also leading the acquisition of the Company’s five other commercial products. He was responsible for Cumberland’s initial public offering and listing on the NASDAQ stock exchange. He also serves as Chairman and Chief Executive Officer of Cumberland Emerging Technologies. Prior to joining our company, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company. As President and Chief Operating Officer, he made key contributions to that company’s growth from its start-up phase through its initial public offering and listing on the London stock exchange. Mr. Kazimi started his career at Brown-Forman Corporation, rising through a series of management positions and helping to launch several new products. Mr. Kazimi serves on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of healthcare companies in the U.S. He also serves on the Boards of the Tennessee Historical Society and the Gettysburg Foundation which partners with the National Park Service to preserve the historic military park. Mr. Kazimi is a member of the Board of Visitors at the Vanderbilt University Business School and the Visiting Committee at the Loyola University New Orleans’ College of Business. He previously served on the board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has sold twice to large private equity investors. He holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt University Owen Graduate School of Management. The Board of Directors believes that Mr. Kazimi brings strategic insight, leadership and a history of successful execution to the Company along with a wealth of experience in both the b
As the Chairman of the Board et Chief Executive Officer of Cumberland Pharmaceuticals, the total compensation of A Kazimi at Cumberland Pharmaceuticals is $1,477,300. There are no executives at Cumberland Pharmaceuticals getting paid more.
A Kazimi is 61, he's been the Chairman of the Board et Chief Executive Officer of Cumberland Pharmaceuticals since 2016. There are 14 older and 5 younger executives at Cumberland Pharmaceuticals. The oldest executive at Cumberland Pharmaceuticals Inc. is Jonathan Griggs, 85, who is the Independent Director.
A's mailing address filed with the SEC is 1600 WEST END AVE., SUITE 1300, NASHVILLE, TN, 37203.
Over the last 15 years, insiders at Cumberland Pharmaceuticals have traded over $4,393,644 worth of Cumberland Pharmaceuticals stock and bought 265,077 units worth $1,208,228 . The most active insiders traders include Joey A Jacobs, Leo Pavliv et Thomas R Lawrence. On average, Cumberland Pharmaceuticals executives and independent directors trade stock every 29 days with the average trade being worth of $10,407. The most recent stock trade was executed by Caroline Young on 1 December 2022, trading 379 units of CPIX stock currently worth $849.
cumberland pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. cumberland is dedicated to providing high quality products which address unmet medical needs.
Cumberland Pharmaceuticals executives and other stock owners filed with the SEC include: